CN103012578A - 一种重组猪白细胞介素2及其编码基因和表达方法 - Google Patents
一种重组猪白细胞介素2及其编码基因和表达方法 Download PDFInfo
- Publication number
- CN103012578A CN103012578A CN2012105849129A CN201210584912A CN103012578A CN 103012578 A CN103012578 A CN 103012578A CN 2012105849129 A CN2012105849129 A CN 2012105849129A CN 201210584912 A CN201210584912 A CN 201210584912A CN 103012578 A CN103012578 A CN 103012578A
- Authority
- CN
- China
- Prior art keywords
- interleukin
- recombinant swine
- swine interleukin
- expression
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010002350 Interleukin-2 Proteins 0.000 title claims abstract description 137
- 102000000588 Interleukin-2 Human genes 0.000 title claims abstract description 130
- 230000014509 gene expression Effects 0.000 title claims abstract description 72
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 49
- 238000004153 renaturation Methods 0.000 claims abstract description 39
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 28
- 241000588724 Escherichia coli Species 0.000 claims abstract description 18
- 241000282898 Sus scrofa Species 0.000 claims description 118
- 241000894006 Bacteria Species 0.000 claims description 50
- 101001043834 Sus scrofa Interleukin-2 Proteins 0.000 claims description 42
- 230000000968 intestinal effect Effects 0.000 claims description 39
- 101001076457 Sus scrofa Interleukin-6 Proteins 0.000 claims description 38
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 31
- 238000001556 precipitation Methods 0.000 claims description 26
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 19
- 239000000243 solution Substances 0.000 claims description 17
- 239000000872 buffer Substances 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 15
- 230000008859 change Effects 0.000 claims description 14
- 238000000502 dialysis Methods 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 12
- 235000015097 nutrients Nutrition 0.000 claims description 11
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 238000010790 dilution Methods 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000007853 buffer solution Substances 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 230000000392 somatic effect Effects 0.000 claims description 5
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 claims description 4
- 238000010612 desalination reaction Methods 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 4
- 239000012139 lysis buffer Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000001291 vacuum drying Methods 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 230000009514 concussion Effects 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 210000001082 somatic cell Anatomy 0.000 claims 1
- 108020004705 Codon Proteins 0.000 abstract description 67
- 230000000694 effects Effects 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 8
- 238000011282 treatment Methods 0.000 abstract description 7
- 230000009465 prokaryotic expression Effects 0.000 abstract description 6
- 238000000746 purification Methods 0.000 abstract description 5
- 208000031295 Animal disease Diseases 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 230000003832 immune regulation Effects 0.000 abstract 1
- 238000009776 industrial production Methods 0.000 abstract 1
- 230000009182 swimming Effects 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 17
- 239000006166 lysate Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108020004999 messenger RNA Proteins 0.000 description 12
- 230000008569 process Effects 0.000 description 11
- 238000013519 translation Methods 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 10
- 238000005457 optimization Methods 0.000 description 9
- 238000000703 high-speed centrifugation Methods 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 229960005486 vaccine Drugs 0.000 description 8
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 239000000975 dye Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000001502 gel electrophoresis Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 229940040731 human interleukin-12 Drugs 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- OJHZNMVJJKMFGX-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;2,3-dihydroxybutanedioic acid Chemical compound OC(=O)C(O)C(O)C(O)=O.O=C([C@@H]1O2)CC[C@H]3[C@]4([H])N(C)CC[C@]13C1=C2C(OC)=CC=C1C4 OJHZNMVJJKMFGX-RNWHKREASA-N 0.000 description 4
- 108700010070 Codon Usage Proteins 0.000 description 4
- 241000588722 Escherichia Species 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000013613 expression plasmid Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 101150039504 6 gene Proteins 0.000 description 3
- 108020004566 Transfer RNA Proteins 0.000 description 3
- 230000006978 adaptation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000012460 protein solution Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 101710117545 C protein Proteins 0.000 description 2
- 108091062157 Cis-regulatory element Proteins 0.000 description 2
- 206010010254 Concussion Diseases 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000979 retarding effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 238000001073 sample cooling Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000007086 side reaction Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 238000003734 CellTiter-Glo Luminescent Cell Viability Assay Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- SPTYHKZRPFATHJ-HYZXJONISA-N dT6 Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 SPTYHKZRPFATHJ-HYZXJONISA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
顺式作用元件 | 优化后 | 优化前 |
E.coli_RBS(AGGAGG) | 0 | 1 |
PolyT(TTTTTT) | 0 | 0 |
PolyA(AAAAAAA) | 0 | 0 |
Ch位点(GCTGGTGG) | 0 | 0 |
T7Cis(ATCTGTT) | 0 | 0 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210584912.9A CN103012578B (zh) | 2012-12-28 | 2012-12-28 | 一种重组猪白细胞介素2及其编码基因和表达方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210584912.9A CN103012578B (zh) | 2012-12-28 | 2012-12-28 | 一种重组猪白细胞介素2及其编码基因和表达方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103012578A true CN103012578A (zh) | 2013-04-03 |
CN103012578B CN103012578B (zh) | 2015-06-17 |
Family
ID=47961726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210584912.9A Active CN103012578B (zh) | 2012-12-28 | 2012-12-28 | 一种重组猪白细胞介素2及其编码基因和表达方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103012578B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105154497A (zh) * | 2015-07-14 | 2015-12-16 | 天津瑞普生物技术股份有限公司 | 一种利用重组大肠杆菌制备鸡白介素2的方法 |
CN106867978A (zh) * | 2015-12-10 | 2017-06-20 | 江苏众红生物工程创药研究院有限公司 | 一种重组高保真dna聚合酶及其编码基因和表达方法 |
CN106893698A (zh) * | 2015-12-17 | 2017-06-27 | 江苏众红生物工程创药研究院有限公司 | 一种重组Taq DNA聚合酶及其编码基因和表达方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1621524A (zh) * | 2003-11-26 | 2005-06-01 | 中国医学科学院基础医学研究所 | 可用于生产人重组白细胞介素-15的原核表达工程菌及纯化方法 |
-
2012
- 2012-12-28 CN CN201210584912.9A patent/CN103012578B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1621524A (zh) * | 2003-11-26 | 2005-06-01 | 中国医学科学院基础医学研究所 | 可用于生产人重组白细胞介素-15的原核表达工程菌及纯化方法 |
Non-Patent Citations (4)
Title |
---|
LI,Y.G.ET AL.: "BAD67214.1", 《GENBANK》, 2 November 2004 (2004-11-02) * |
郭小参等: "猪白细胞介素-2基因在大肠杆菌中的表达及其生物学活性测定", 《西北农林科技大学学报(自然科学版)》, vol. 37, no. 11, 10 November 2009 (2009-11-10), pages 1 - 6 * |
高见等: "密码子优化的HPV16 L2E7基因在大肠杆菌中高效表达", 《中国医学科学院学报》, vol. 29, no. 05, 30 October 2007 (2007-10-30), pages 579 - 583 * |
魏凡华等: "猪白细胞介素2基因的克隆和酵母表达", 《黑龙江畜牧兽医》, no. 12, 10 December 2008 (2008-12-10), pages 13 - 15 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105154497A (zh) * | 2015-07-14 | 2015-12-16 | 天津瑞普生物技术股份有限公司 | 一种利用重组大肠杆菌制备鸡白介素2的方法 |
CN106867978A (zh) * | 2015-12-10 | 2017-06-20 | 江苏众红生物工程创药研究院有限公司 | 一种重组高保真dna聚合酶及其编码基因和表达方法 |
CN106893698A (zh) * | 2015-12-17 | 2017-06-27 | 江苏众红生物工程创药研究院有限公司 | 一种重组Taq DNA聚合酶及其编码基因和表达方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103012578B (zh) | 2015-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103059124B (zh) | 一种重组猪干扰素γ及其编码基因和表达方法 | |
CN102146135A (zh) | 一种重组类人胶原蛋白及其生产方法 | |
CN101736062B (zh) | 一种重组猪α干扰素标准品的制备方法 | |
CN103570836B (zh) | 一种重组猪干扰素β1-Fc融合蛋白及其编码基因和表达方法 | |
CN103193887B (zh) | 一种重组猪白细胞介素2-Fc融合蛋白及其编码基因和表达方法 | |
CN103012577B (zh) | 一种重组猪白细胞介素4及其编码基因和表达方法 | |
CN103059122B (zh) | 一种重组猪干扰素α1及其编码基因和表达方法 | |
CN103012578B (zh) | 一种重组猪白细胞介素2及其编码基因和表达方法 | |
CN104371025B (zh) | 一种针对***具有免疫原性的蛋白及其应用 | |
CN103936862A (zh) | 猪白细胞介素4/6、2基因共表达及其在制备生物制剂中的应用 | |
CN103710367B (zh) | 一种重组人激肽释放酶1及其编码基因和制备方法 | |
CN103265637B (zh) | 一种重组猪白细胞介素4-Fc融合蛋白及其编码基因和表达方法 | |
CN102796200B (zh) | 一种杂合肽囊素佐剂及其制备方法和应用 | |
CN103059123B (zh) | 一种重组猪干扰素β1及其编码基因和表达方法 | |
CN103232545A (zh) | 一种重组猪干扰素α1-Fc融合蛋白及其编码基因和表达方法 | |
CN103232544B (zh) | 一种重组猪干扰素γ-Fc融合蛋白及其编码基因和表达方法 | |
CN100445371C (zh) | 一种利用大肠杆菌生产人α防御素1蛋白的方法 | |
CN108948163A (zh) | 澳洲坚果植物防御素及其应用 | |
CN103215274B (zh) | 斜带石斑鱼干扰素IFNγ2及其制备方法和应用 | |
CN103319590B (zh) | 栉孔扇贝肽聚糖识别蛋白(CfPGRP-S1)的应用 | |
CN102978214B (zh) | 鸡-γ-干扰素基因序列,其重组工程菌及应用 | |
CN102154306A (zh) | 密码子优化的猪cd40l基因及表达其编码蛋白的重组杆状病毒的制备方法 | |
CN107435045A (zh) | 一种优化重组人白细胞介素‑2的核苷酸序列及高效可溶性表达方法 | |
CN109593766A (zh) | 草鱼铁调素基因及其编码的重组蛋白和应用 | |
CN1100881C (zh) | 人、猪共患囊虫病核酸疫苗 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 213125 Jiangsu city of Changzhou Province Cloud River New District No. 518 Changzhou Qianhong biochemical pharmaceutical biological all red Patentee after: ZonHon Biopharma Institute Inc. Patentee after: Changzhou Gensun Institute of Biomedicine Co., Ltd. Address before: 213022 the Yellow River Middle Road, Xinbei District, Jiangsu, China, No. 132, No. Patentee before: ZonHon Biopharma Institute Inc. Patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. |
|
CP02 | Change in the address of a patent holder |
Address after: 213125, Yunhe Road, Xinbei District, Jiangsu, Changzhou, 518 Co-patentee after: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 Jiangsu city of Changzhou Province Cloud River New District No. 518 Changzhou Qianhong biochemical pharmaceutical biological all red Co-patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
CP02 | Change in the address of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee after: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Patentee after: ZonHon Biopharma Institute Inc. Address before: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee before: Changzhou Gensun Institute of Biomedicine Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190425 Address after: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Patentee after: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Address before: 213125 No. 518 Yunhe Road, Xinbei District, Changzhou City, Jiangsu Province Co-patentee before: Jiangsu Jingsen Biomedical New Materials Technology Co., Ltd. Patentee before: ZonHon Biopharma Institute Inc. |
|
TR01 | Transfer of patent right |